This Article Full Text Full Text (PDF) All Versions of this Article: 38/2/417    most recent 01.STR.0000254504.71955.05v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Aleu, A. Articles by Schellinger, P. D. Search for Related Content PubMed PubMed Citation Articles by Aleu, A. Articles by Schellinger, P. D. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Thrombolysis Acute Cerebral Infarction Emergency treatment of Stroke

(Stroke. 2007;38:417.)
© 2007 American Heart Association, Inc.

Comments, Opinions, and Reviews

Hemorrhagic Complications After Off-Label Thrombolysis for Ischemic Stroke

From the Neurointensive Care Unit, Department of Neurology (A.A., P.M., C.L., M.K., P.D.S.), University of Heidelberg, Heidelberg, Germany; Universitat Autònoma de Barcelona (A.A.), Barcelona, Spain; the Departamento de Neurología (P.M.), Pontificia Universidad Católica, Santiago, Chile; and the Department of Neurology (P.D.S.), University of Erlangen, Erlangen, Germany.

Correspondence to Aitziber Aleu, Department of Neurology, Neurointensive Care Unit, University of Heidelberg, Im Neuenheimer Feld 400, Postal Code: 69120, Heidelberg, Germany. E-mail: aitziberaleu{at}gmail.com

Background and Purpose— Only 2% to 4% of patients with acute ischemic stroke receive thrombolytic therapy resulting from the current strict inclusion criteria among other issues. Safety of intravenous and intraarterial thrombolysis in off-label situations is controversially discussed. We sought to review the reports on such patients regarding intra- and extracranial hemorrhage.

Summary of Review— A MEDLINE search for off-label uses of thrombolysis revealed reports on 273 patients treated with intraarterial or intravenous thrombolysis for ischemic stroke. Symptomatic intracranial hemorrhage occurred in 19 of 273 patients (6.95%) and extracranial hemorrhage in 17 of 273 (6.22%).

Conclusions— These data suggest that the overall bleeding risk in off-label thrombolysis may not be as high as presumed. However, the small number of patients in each group and the likely underreporting of worse outcomes preclude drawing any conclusion as to specific treatment recommendations. Selected patients might benefit, however, from thrombolysis in situations not currently considered in the inclusion criteria. To obtain a meaningful database, a registry for off-label thrombolysis should be created.

Key Words: safety • symptomatic intracranial hemorrhage • thrombolysis